23 articles | last updated: Jun 11 22:38:47
Eli Lilly's new treatment shows potential in slowing cognitive decline but raises safety and accessibility concerns.
- The FDA advisory committee voted unanimously in favor of donanemab, citing its effectiveness in early-stage Alzheimer's.
- Donanemab targets amyloid plaques in the brain, slowing disease progression by 22% in early-stage patients.
- Key safety concerns include brain inflammation and bleeding, particularly in genetically predisposed individuals.
- The panel highlighted the need for more research on the drug's effects in underrepresented racial and ethnic groups.
- Final FDA approval is pending, with potential implications for broader Alzheimer's treatment strategies.
People, Places and Things In This Story
- Food and Drug Administration Federal agency
- Alzheimer's disease Disease
- Donanemab Drug
- Eli Lilly and Company Pharmaceutical company
Categories:
- Healthcare
- Health
- Business
- Science
- Government
- Finance
- Society